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Abbreviations: Gem: gemcitabine, FOLFIRINOX: 5-flourouracil, leucovorin, irinotecan and oxaliplatin, Cap: capecitabine, S1: tegafur/gimeracil/oteracil, Pac: 
nab-paclitaxel.
*31 patients with other regimens as initial treatment than those listed were excluded.
Regimen* Patients  No.
Median overall survival, months  
(95% confidence interval)
Gem monotherapy 938   5.1  (4.8- 5.6)
FOLFIRINOX 435 10.0  (9.2-11.0)
GemCap 134   8.4   (6.9-9.1)
GemS1 114   8.9   (7.2-10.3)
GemPac 94   6.7   (5.5-8.7)
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ResultsBackground
Nationwide data on the efficacy of primary treatment on overall 
survival (OS) in an entirely unselected population of patients with 
pancreatic cancer (PC) have not been reported before. 
Material and Methods
• From 1 May 2011 to 30 April 2016, 4260 patients were identified in the 
national Danish Pancreatic Cancer Database (DPCD), Figure 1.
• Patients’ characteristics are presented in Table 1.
• OS was analysed from the date of the initial treatment, either resection 
or chemotherapy or from the date of diagnosis in case of best supportive 
care (BSC). Last clinical follow-up was 10 September 2017.
• Treatment and clinical outcome are presented in Figure 2, Table 2 
and Figure 3.
• Resected lymph node negative patients had the longest survival.
• Patients initially treated with chemotherapy (mono or combination) 
had slightly shorter median OS than found in randomised  
controlled trials. 
• The outcome of gemcitabine monotherapy was poor, possibly  
reflecting less treatment effect and selection of less fit patients. 
• To reduce the group of BSC patients, new diagnostic methods 
are required.
Conclusion
Resection
Lymph node metastases* Patients  No.
Median overall survival, months  
(95% confidence interval)
N- 215 36.9 (28.6-44.7)
N+ 465 17.5 (15.4-20.1)
Abbreviations; N-: Without lymph node metastases, N+: With lymph node metastases.
*38 patients without histopathological reports on lymph node status were excluded. 
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Figure 1
*Excluded: Preoperative/neoadjuvant chemotherapy followed by resection: 56, other malignancies: 26, incorrect registration of treatment: 13, lost to follow-up: 2. 
Excluded*
N=97
PC
N=4260
Included
N=4163
Resection
N=718
(17%)
Chemotherapy
N=1746
(43%)
Best supportive care
N=1699
(40%)
Aim
To investigate the effect of initial treatment on OS in all patients with 
PC in Denmark diagnosed in a recent five-year period.
Chemotherapy
Resection  
(n=718)
Chemotherapy  
(n=1746)
BSC  
(n=1699)
All  
(n=4163)
Age;years (median and range) 67 (13-86) 68 (34-90) 74 (24-100) 70 (13-100)
Gender
Female 338 (47%) 813 (47%) 843 (50%) 1994 (48%)
Male 380 (53%) 933 (53%) 856 (50%) 2164 (52%)
Charlson comorbidity index
0-2 561 (78%) 1301 (75%) 1024 (60%) 2886 (69%)
>3 157 (22%) 445 (25%) 675 (40%) 1277 (31%)
M-status*
0 718 (100%) 905 (52%) 847 (50%) 1752 (51%)
1 0 (0%) 841 (48%) 852 (50%) 1693 (49%)
Diagnosis
Pathology 718 (100%) 1642 (94%) 1288 (76%) 3648 (88%)
Clinical 0 (0%) 104 (6%) 411 (24%) 515 (12%)
Abbreviation; BSC: Best suppotive care. 
* M-status; M1: patients coded with metastatic disease in DPCD within 60 days from diagnosis.
Table 1
Treatment PatientsNo.
Median overall survival, months  
(95% confidence interval)
Resection 718 21.9 (20.0-24.2)
Chemotherapy 1746 6.9 (6.4-7.3)
BSC* 1697 1.6 (1.5-1.7)
Abbreviation; BSC: Best supportive care. 
*Two patients were excluded from the survival analyses due to diagnosis date = date of death.
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